ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C0451022 | A twenty-one question survey completed by a patient, with each answer scored on a scale of 0 to 3, designed to measure presence of depression. | Beck Depression Inventory|becks depression inventory|Beck depression inventory|Beck depression inventory (assessment scale)|BDI - Beck depression inventory|beck depression inventory|BDI|bdi | Beck depression inventory |
C0017837 | A transferase that catalyzes the addition of aliphatic, aromatic, or heterocyclic FREE RADICALS as well as EPOXIDES and arene oxides to GLUTATHIONE. Addition takes place at the SULFUR. It also catalyzes the reduction of polyol nitrate by glutathione to polyol and nitrite. | Ligandin|Transferases, Glutathione|glutathiones transferase|glutathione S-transferase|Glutathione S-Alkyltransferase|Glutathione S-aralkyltransferase|Glutathione transferase|glutathione aralkyltransferase|glutathione s transferase|Glutathione S-alkyltransferase|S-(hydroxyalkyl)glutathione lyase|Glutathione S-Aryltransferase|Glutathione S-Aralkyltransferase|Glutathione Lyase, S-Hydroxyalkyl|Glutathione Transferase|S-Hydroxyalkyl Glutathione Lyase|Glutathione S-Epoxidetransferase|glutathione s-transferase|Glutathione Transferases|Glutathione S Epoxidetransferase|Transfer Protein, Heme|S-(Hydroxyalkyl)Glutathione Lyase|glutathione transferases|Glutathione S-Transferase|Glutathione Organic Nitrate Ester Reductase|Glutathione S transferase|Ligandins|Glutathione S Alkyltransferase|GST - Glutathione S transferase|glutathione aryltransferase|S-Transferase, Glutathione|Glutathione S Transferase|Glutathione S Aryltransferase|Heme Transfer Protein|Lyase, S-Hydroxyalkyl Glutathione|Glutathione transferase (substance)|Protein, Heme Transfer|EC 2.5.1.18|S-Alkyltransferase, Glutathione|S-Aryltransferase, Glutathione|Glutathione S-aryltransferase|Transferase, Glutathione|glutathione transferase|S-Epoxidetransferase, Glutathione|RX:glutathione R-transferase|GST|S Hydroxyalkyl Glutathione Lyase|ligandin | Glutathione S-Transferase |
C0069227 | null | GSTS|O-(glucuronic acid 2-sulfate)-(1--3)-O-(2,5)-andydrotalitol 6-sulfate | O-(glucuronic acid 2-sulfate)-(1--3)-O-(2,5)-andydrotalitol 6-sulfate |
C0066468 | null | 2-chloro-N-(2-ethyl-6-methylphenyl)-N-(2-methoxyethyl)acetamide | metolachlor |
C0250512 | null | 4-(dichloroacetyl)-3,4-dihydro-3-methyl-2H-1,4-benzoxazine|Ethanone, 2,2-dichloro-1-(2,3-dihydro-3-methyl-4H-1,4-benzoxazin-4-yl)- | benoxacor |
C1098215 | null | Xcytrin | Xcytrin |
C0964264 | A substance that is being studied in the treatment of cancer. It may make tumor cells more sensitive to radiation therapy, improve tumor images using magnetic resonance imaging (MRI), and kill cancer cells. It is a type of metalloporphyrin complex. | Gd(III) texaphyrin|Gd-Tex|Motexafin gadolinium|MOTEXAFIN GADOLINIUM|gadolinium texaphyrin complex|motexafin gadolinium|Motexafin Gadolinium|Gadolinium Texaphyrin|Gd (III) Texaphryin|Gadolinium texaphyrin|gadolinium texaphyrin | motexafin gadolinium |
C0032712 | A group of compounds containing the porphin structure, four pyrrole rings connected by methine bridges in a cyclic configuration to which a variety of side chains are attached. The nature of the side chain is indicated by a prefix, as uroporphyrin, hematoporphyrin, etc. The porphyrins, in combination with iron, form the heme component in biologically significant compounds such as hemoglobin and myoglobin. | Porphyrins|porphyrins|Porphyrin (substance)|Porphyrin, NOS|porphyrin|Porphyrin | Porphyrins |
C0964264 | A substance that is being studied in the treatment of cancer. It may make tumor cells more sensitive to radiation therapy, improve tumor images using magnetic resonance imaging (MRI), and kill cancer cells. It is a type of metalloporphyrin complex. | Gd(III) texaphyrin|Gd-Tex|Motexafin gadolinium|MOTEXAFIN GADOLINIUM|gadolinium texaphyrin complex|motexafin gadolinium|Motexafin Gadolinium|Gadolinium Texaphyrin|Gd (III) Texaphryin|Gadolinium texaphyrin|gadolinium texaphyrin | motexafin gadolinium |
C1332285 | An anaplastic meningioma that arises within the cranial cavity. | null | Anaplastic (Malignant) Intracranial Meningioma |
C1332285 | An anaplastic meningioma that arises within the cranial cavity. | null | Anaplastic (Malignant) Intracranial Meningioma |
C1337010 | A well differentiated extraskeletal myxoid chondrosarcoma. | Well Differentiated Extraskeletal Myxoid Chondrosarcoma|Extraskeletal Well Differentiated Myxoid Chondrosarcoma|Well Differentiated Extraosseous Myxoid Chondrosarcoma | Conventional Extraskeletal Myxoid Chondrosarcoma |
C1337010 | A well differentiated extraskeletal myxoid chondrosarcoma. | Well Differentiated Extraskeletal Myxoid Chondrosarcoma|Extraskeletal Well Differentiated Myxoid Chondrosarcoma|Well Differentiated Extraosseous Myxoid Chondrosarcoma | Conventional Extraskeletal Myxoid Chondrosarcoma |
C0007422 | Agents that are used to stimulate evacuation of the bowels. | purgative|cathartics|Cathartic (substance)|Cathartic, NOS|Purgative|cathartic|Bowel Evacuants|Purgative, NOS|Evacuants, Bowel|Cathartics|Purgatives|Cathartic|purgatives | Cathartics |
C0524869 | The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted. | Allelic Loss|loh|Heterozygosity, Loss of|Heterozygosity Loss|loss of heterozygosity (LOH)|Loss of Heterozygosity|Allelic Losses|loss of heterozygosity|LOH | Loss of Heterozygosity |
C0887935 | A situation where one member (allele) of a gene pair is lost (LOSS OF HETEROZYGOSITY) or amplified. | Allele Imbalance|Allelic Imbalances|Allelic Imbalance|Imbalances, Allelic|Imbalance, Allelic | Allelic Imbalance |
C1336076 | A carcinoma that arises from the breast and is not caused by inherited genetic mutations. | Sporadic Breast Cancer | Sporadic Breast Carcinoma |
C1511022 | A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA1 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA1 gene. Approximately 75% of these alterations result in a truncated form of the breast cancer type 1 susceptibility protein. Mutations in the BRCA1 gene predispose individuals to breast and ovarian cancers. | BROVCA1 Gene Mutation|BRCA1 Mutation|Mutation of the BRCA1 Gene|BRCA1 Gene Mutation|Breast Cancer Type 1 Susceptibility Gene Mutation|Breast Cancer 1 Gene Mutation|Breast Cancer 1, Early Onset Gene Mutation | BRCA1 Gene Mutation |
C1336605 | This gene is involved in the negative regulation of telomerase activity. | telomeric repeat binding factor 2|TERF2 Gene|TERF2|TELOMERIC REPEAT-BINDING FACTOR 2|Telomeric Repeat Binding Factor 2 Gene|TRF2|TERF2 gene | TERF2 gene |
C1336605 | This gene is involved in the negative regulation of telomerase activity. | telomeric repeat binding factor 2|TERF2 Gene|TERF2|TELOMERIC REPEAT-BINDING FACTOR 2|Telomeric Repeat Binding Factor 2 Gene|TRF2|TERF2 gene | TERF2 gene |
C0729594 | One of approximately 20-30 lymph nodes in chain formation that traverse the concavity of the underarm to the clavicle. | Axillary Lymph Node|Axillary lymph nodes|Axillary lymph node group|Lymph node group of axilla|lymph nodes axillary|Axillary lymph node group (body structure)|Set of axillary lymph nodes|ALN|LYMPH NODE, AXILLARY|Axillary node|axillary lymph node|axillary nodes|Axillary Lymph Nodes|AXILLARY LYMPH NODE|Nodi lymphoidei axillares|Axillary lymph nodes set|Axillary lymph node structure (body structure)|Axillary Node|Axillary lymph node structure|Axillary lymph node|Axillary lymph node, NOS|axillary node|axillary lymph nodes | Axillary lymph node group |
C0244404 | The active ingredient in a drug used to reduce the risk of invasive breast cancer in postmenopausal women who are at high risk of the disease or who have osteoporosis. It is also used to prevent and treat osteoporosis in postmenopausal women. It is also being studied in the prevention of breast cancer in certain premenopausal women and in the prevention and treatment of other conditions. Raloxifene blocks the effects of the hormone estrogen in the breast and increases the amount of calcium in bone. It is a type of selective estrogen receptor modulator (SERM). | Raloxifenum|raloxifene|Raloxifeno|RALOXIFENE|Raloxifène|Raloxifene-containing product|(2-(4-Hydroxyphenyl)-6-hydroxybenzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone|[6-Hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone|Raloxifene (substance)|Keoxifene|Product containing raloxifene (medicinal product)|Raloxifene | raloxifene |
C0132555 | Expressed in various cell types, Nitric Oxide Synthases (NOS Family) are constitutive or inducible calcium/calmodulin stimulated homodimers stabilized by BH4 that bind FAD and FMN cofactors, generally contain a flavodoxin-like domain, and synthesize reactive free radical nitric oxide messenger from L-arginine. NO can act as a neurotransmitter and has antimicrobial and antitumoral activities in macrophages. IL12 requires NOS to stimulate tyrosine-phosphorylation of STAT4 by TYK2 in NK cytotoxicity. Vascular NO (endothelia) inhibits muscle contraction through a cGMP pathway, inhibits platelet aggregation, and mediates VEGF-induced angiogenesis. Endothelial AKT phosphorylates and enhances NOS activity. Potentially influencing energy balance, NO can trigger cGMP-dependent mitochondrial biogenesis mediated by induction of the master regulator PPARGC1. (NCI) | nitric oxide synthase|nitric oxide synthetase|NOS|NO Synthase|synthase|Nitric-oxide synthase|Synthase, Nitric Oxide|Oxide Synthase, Nitric|Nitric-oxide synthase (substance)|Endothelium-derived relaxing factor synthase|nitric oxide synthases|NOS Family|Nitric Oxide Synthetase|Nitric Oxide Synthase Family|Nitric-Oxide Synthetase|Nitric Oxide Synthase|NADPH-Diaphorase|NO synthase|EC 1.14.13.39|Endothelium-derived relaxation factor-forming enzyme|L-Arginine,NADPH:oxygen oxidoreductase (nitric-oxide-forming)|Nitric-Oxide Synthase | Nitric Oxide Synthase |
C1334274 | A carcinoma that is not confined to the epithelium, and has spread to the surrounding stroma. | Invasive Carcinoma | Invasive Carcinoma |
C0002793 | Loss of structural differentiation and useful function of neoplastic cells. | Anaplastic Lesion|Anaplasia|Anaplastic Change|Anaplasias|Dedifferentiation|Dedifferentiation (morphologic abnormality)|anaplasia|dedifferentiation | Anaplasia |
C1167268 | Projection at the leading edge of a crawling cell; the protrusions are supported by a microfilament meshwork. [ISBN:0124325653] | Ruffle|ruffle | Ruffle |
C0039984 | A neurovascular syndrome associated with compression of the BRACHIAL PLEXUS; SUBCLAVIAN ARTERY; and SUBCLAVIAN VEIN at the superior thoracic outlet. This may result from a variety of anomalies such as a CERVICAL RIB, anomalous fascial bands, and abnormalities of the origin or insertion of the anterior or medial scalene muscles. Clinical features may include pain in the shoulder and neck region which radiates into the arm, PARESIS or PARALYSIS of brachial plexus innervated muscles, PARESTHESIA, loss of sensation, reduction of arterial pulses in the affected extremity, ISCHEMIA, and EDEMA. (Adams et al., Principles of Neurology, 6th ed, pp214-5). | Thoracic outlet syndrome (disorder)|Thoracic Outlet Neurovascular Syndrome|THORACIC OUTLET SYNDROME|Outlet Syndrome, Thoracic|Syndrome, Thoracic Outlet|TOS|Aperture Syndrome, Thoracic Outlet|outlet syndrome thoracic|thoracic outlet syndromes|TOS - Thoracic outlet syndrome|Neurovascular Syndrome, Thoracic Outlet|Thoracic outlet syndrome|Thoracic Outlet Syndrome|Outlet Syndromes, Thoracic|outlet syndromes thoracic|Thoracic Outlet Syndromes|Superior Thoracic Aperture Syndrome|CERVICOTHORACIC OUTLET SYNDROME|Syndromes, Thoracic Outlet|thoracic outlet syndrome | Thoracic Outlet Syndrome |
C0541435 | An injury that results in paralysis of the muscles of the shoulder, arm, and hand. It manifests as lack of mobility in the arm. In the majority of cases there is spontaneous recovery. | Paralysis, brachial plexus|Palsy, brachial plexus|palsy brachial plexus|Palsies of the Brachial Plexus|brachial plexus paralysis|paralysis brachial plexus|brachial plexus palsy | Brachial Plexus Palsy |
C0150600 | null | Recommendation to (procedure)|advice therapy|Advice to|Recommendation to|guidance|advices|advice | Advice |
C1281159 | null | Entire endolymphatic sac (body structure)|Entire endolymphatic sac | Entire endolymphatic sac |
C1279054 | null | Entire temporal bone (body structure)|Entire temporal bone | Entire temporal bone |
C0447557 | The main pancreatic duct is the larger of the two pancreatic ducts. It transverses through the body of the PANCREAS and opens into the duodenum at the major duodenal papilla. | Wirsung duct|Wirsung Duct|Duct, Wirsung's|wirsung duct|Chief pancreatic duct|duct of wirsung|Main pancreatic duct|Main duct of pancreas|Main Pancreatic Duct|Wirsungs Duct|Structure of duct of Wirsung (body structure)|Duct, Main Pancreatic|Structure of duct of Wirsung|Wirsung's Duct|Pancreatic Duct, Main|Main Pancreatic Ducts|Duct of Wirsung | Main pancreatic duct |
C0004704 | An endoscopic therapeutic procedure in which a balloon device is used to dilate a narrowed lumen. | balloon dilations|balloon dilatation|Balloon Dilation|Balloon|ballooning|balloon dilation | Balloon Dilatation |
C0003855 | An abnormal direct communication between an artery and a vein without passing through the CAPILLARIES. An A-V fistula usually leads to the formation of a dilated sac-like connection, arteriovenous aneurysm. The locations and size of the shunts determine the degree of effects on the cardiovascular functions such as BLOOD PRESSURE and HEART RATE. | Pathologic Arteriovenous Fistula|Arteriovenous shunt|Arteriovenous fistula (morphologic abnormality)|fistula arteriovenous|arteriovenous aneurysm|Fistula, Arteriovenous|a v fistulas|Pathologic AV Fistula|AV Fistula|Arteriovenous fistulas|Arteriovenous Fistula|Arteriovenous fistula|FISTULA, ARTERIOVENOUS|Fistulas, Arteriovenous|Arteriovenous Fistulas|arteriovenous shunt|a v fistula|av fistulas|a-v fistula|arterio-venous fistula|av fistula|fistulas arteriovenous|FISTULA ARTERIOVENOUS|AV - Arteriovenous fistula|arteriovenous fistulas|Arteriovenous fistula (disorder)|arteriovenous fistula|arteriovenous av fistula | Arteriovenous fistula |
C0226841 | A vein located in the upper thigh that connects, through tributaries, to the popliteal and inferior gluteal veins, and joins the superficial femoral vein at the groin to form the common femoral vein. | PROFUNDA FEMORIS VEIN|Vena profunda femoris|Deep femoral vein|Structure of profunda femoris vein (body structure)|Deep Femoral Vein|Structure of profunda femoris vein|Deep vein of thigh|V. profunda femoris|Profunda femoris vein | Structure of profunda femoris vein |
C0016169 | Abnormal communication most commonly seen between two internal organs, or between an internal organ and the surface of the body. | fistulas|fistulous tract|Fistulas|Sinus|Abnormal sinus tract|Abnormal sinus tract, NOS|Fistulous tract, NOS|fistula|Fistula, NOS|Sinus (morphologic abnormality)|FISTULA|Pathologic Fistula|Fistula (morphologic abnormality)|Fistula|Fistulous tract|Fistula (disorder) | pathologic fistula |
C0018994 | Hemorrhage in or through the BILIARY TRACT due to trauma, inflammation, CHOLELITHIASIS, vascular disease, or neoplasms. | hemobilia|Hematobilia|Hemorrhage in bile|haemobilia|Hemobilias|haematobilia|Haemobilia|HEMOBILIA|Biliary Tract Hemorrhages|hematobilia|Hemobilia (disorder)|Biliary Tract Hemorrhage|Hemobilia|Haemorrhage in bile|Haematobilia|Hemorrhage, Biliary Tract | Biliary Tract Hemorrhage |
C0545733 | null | Vertebrobasilar arterial system|Vertebral and basilar artery|vertebral basilar artery|Vertebrobasilar | vertebrobasilar |
C0016295 | Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy. | flunarizin|Flunarizin|Flunarizine|Flunarizina|FLUNARIZINE|Flunarizine (substance)|Piperazine, 1-(bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)-, (E)-|Flunarizinum|flunarizine | flunarizine |
C1279986 | null | heart procedure|cardiac procedure|Heart procedure|Procedure on heart|cardiac procedures|Procedure on heart (procedure)|heart procedures | Procedure on heart |
C1521321 | A chromosome band present on 3q | null | 3q26 |
C0031678 | A group of hydrolases which catalyze the hydrolysis of monophosphoric esters with the production of one mole of orthophosphate. | Substance with phosphoric monoester hydrolase mechanism of action (substance)|Phosphomonoesterase|phosphoric monoester hydrolase|phosphatase|Hydrolases, Phosphoric Monoester|Phosphatase|phosphatases|Phosphohydrolase|phosphomonoesterases|Phosphoric monoester hydrolase|EC 3.1.3.-|Phosphomonoesterases|phosphomonoesterase|Phosphoric Monoester Hydrolases|Phosphatases|phosphoric monoester hydrolases|Phosphohydrolases | Phosphoric Monoester Hydrolases |
C1281776 | null | Entire notochord|Entire notochord (body structure) | Entire notochord |
C1336789 | Transcription Repressor/Corepressor Gene encodes Transcriptional Repressor/Corepressor, proteins that can regulate transcription by binding to the operator and causing repression. (from Glick: Glossary of Biochemistry and Molecular Biology) | Transcriptional Repressor/Corepressor|Transcriptional Corepressor|Transcription Repressor|Transcriptional Repressor|Repressor|Transcription Corepressor | Transcription Repressor/Corepressor |
C0525390 | null | Fatty Acid Binding Proteins, Adipocyte Specific|Adipocyte Lipid Binding Protein|Adipocyte Specific Fatty Acid Binding Protein|Adipocyte-Specific Fatty Acid-Binding Protein | Fatty Acid-Binding Proteins, Adipocyte-Specific |
C0597716 | A protein which binds to an enhancer. Typically, it binds to a cis enhancer element and modifies the transcriptional activity of the associated gene. | enhancer binding protein|EBP|Enhancer Binding Protein | Enhancer Binding Protein |
C0026650 | Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions. | Movement Disorders|Dyskinesia Syndrome|movement disorder|MOVEMENT DISORDER|Movement disorder, NOS|Unusual movement|Movement disorder (disorder)|Movement disorders|Abnormality of movement|Movement disorder|Unusual movements|MOVEMENT DISORDERS|MOVEMENT DISORDER (NOS)|DYSKINESIA SYNDROME|Movement Disorder Syndromes|movement disorders|Dyskinesia Syndromes|Movement Disorder|Movement Disorder Syndrome | Movement Disorders |
C0014695 | A form of vitamin D that helps the body use calcium and phosphorus to make strong bones and teeth. It is fat-soluble (can dissolve in fats and oils) and is found in plants and yeast. It can be made in the body from another form of vitamin D when the body is exposed to the sun. Ergocalciferol is also made in the laboratory. It is used to prevent and to treat vitamin D deficiency. It is a type of dietary supplement. | Ergocalciferol|Ergocalciferol preparation|Ergocalciférol|9,10-secoergosta-5,7,10(19),22-tetraen-3-beta-ol|Ergocalciferolum|Ergocalciferol (substance)|Vitamin D|Ercalciol|Calciferol|Ergocalciferol-containing product|9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol|Viosterol preparation|(3β,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol|D2, Vitamin|(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol|ergocalciferol|Activated ergosterol|vitamin d2|Vitamin D2|Viosterol|vitamin D2|Vitamin D2 preparation|Vitamina D2|Oleovitamin D2|Vitamin D 2|Activated ergosterol preparation|(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol|ERGOCALCIFEROL|calciferol|Product containing ergocalciferol (medicinal product)|Calciferol preparation | ergocalciferol |
C0102118 | A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis. | alendronate|Alendronate (substance)|4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate|Alendronate|Aminohydroxybutane Bisphosphonate|ALENDRONATE|(4-Amino-1-hydroxybutylidene)bisphosphonic Acid | alendronate |
C0014695 | A form of vitamin D that helps the body use calcium and phosphorus to make strong bones and teeth. It is fat-soluble (can dissolve in fats and oils) and is found in plants and yeast. It can be made in the body from another form of vitamin D when the body is exposed to the sun. Ergocalciferol is also made in the laboratory. It is used to prevent and to treat vitamin D deficiency. It is a type of dietary supplement. | Ergocalciferol|Ergocalciferol preparation|Ergocalciférol|9,10-secoergosta-5,7,10(19),22-tetraen-3-beta-ol|Ergocalciferolum|Ergocalciferol (substance)|Vitamin D|Ercalciol|Calciferol|Ergocalciferol-containing product|9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol|Viosterol preparation|(3β,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol|D2, Vitamin|(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol|ergocalciferol|Activated ergosterol|vitamin d2|Vitamin D2|Viosterol|vitamin D2|Vitamin D2 preparation|Vitamina D2|Oleovitamin D2|Vitamin D 2|Activated ergosterol preparation|(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol|ERGOCALCIFEROL|calciferol|Product containing ergocalciferol (medicinal product)|Calciferol preparation | ergocalciferol |
C0019557 | Fractures of the FEMUR HEAD; the FEMUR NECK; (FEMORAL NECK FRACTURES); the trochanters; or the inter- or subtrochanteric region. Excludes fractures of the acetabulum and fractures of the femoral shaft below the subtrochanteric region (FEMORAL FRACTURES). | Fracture, Hip|fracture of hip|broken hips|hip fracture|Hip Fractures|broken hip|hip fx|hip fractures|Fracture of hip|fractured hip|fractured hips|HIP FRACTURE|Fractures, Hip|Fracture of hip, NOS|Hip fracture|Hip Fracture | Hip Fractures |
C0393571 | A syndrome complex composed of three conditions which represent clinical variants of the same disease process: STRIATONIGRAL DEGENERATION; SHY-DRAGER SYNDROME; and the sporadic form of OLIVOPONTOCEREBELLAR ATROPHIES. Clinical features include autonomic, cerebellar, and basal ganglia dysfunction. Pathologic examination reveals atrophy of the basal ganglia, cerebellum, pons, and medulla, with prominent loss of autonomic neurons in the brain stem and spinal cord. (From Adams et al., Principles of Neurology, 6th ed, p1076; Baillieres Clin Neurol 1997 Apr;6(1):187-204; Med Clin North Am 1999 Mar;83(2):381-92) | Atrophies, Multisystem|Multiple system atrophy|Multisystemic Atrophies|Multisystem Atrophy|Multisystem Atrophies|Multiple System Atrophies|multisystem atrophy|atrophy multiple system|multiple system atrophy|Multiple System Atrophy Syndrome|Multisystemic Atrophy|Atrophy, Multiple System|Multiple system atrophy (disorder)|Atrophy, Multisystem|Multiple System Atrophy|Atrophies, Multisystemic|Atrophy, Multisystemic|atrophy multiple systems|Shy-Drager Syndrome|MSA - Multiple system atrophy | Multiple System Atrophy |
C0004781 | Large subcortical nuclear masses derived from the telencephalon and located in the basal regions of the cerebral hemispheres. | Basal ganglion structure|Basal ganglia|Basal nucleus|Ganglia, Basal|basal ganglia|Basal nuclei structure|Set of basal ganglia|Set of basal nuclei|Basal Nuclear Complex|Basal ganglion|Basal ganglion structure (body structure)|Ganglion, Basal|Basal Nuclei|Basal nucleus structure|Nuclear Complex, Basal|Basal Ganglia|BASAL GANGLIA|Basal Nuclear Complices|Basal ganglia set|basal ganglion|basal nuclei|Nuclei, Basal|BRAIN, BASAL GANGLIA|Basal ganglia, NOS | Basal Ganglia |
C0752205 | null | Dystonias, Secondary|secondary dystonia|Secondary Dystonias|Secondary Dystonia | Dystonia, Secondary |
C0181839 | An optical instrument that uses a combination of lenses to produce magnified images of very small objects | Microscope Device|microscopes|Microscope|Microscope, NOS|Microscope, device|Microscope, device (physical object)|microscope | Microscopes |
C0242506 | Fluorescent spectroscopy or fluorometry is a type of electromagnetic spectroscopy used for analyzing fluorescent spectra. It involves using a beam of light, usually ultraviolet light, that excites the electrons in molecules of certain compounds and causes them to emit light of a lower energy, typically, but not necessarily, visible light. | Fluorescence spectroscopy|fluorescence spectroscopy|PMS|photon migration spectroscopy|Spectroscopy, Fluorescence|Fluorescence Spectroscopy | Fluorescence Spectroscopy |
C0598988 | Signal-mediated nuclear import and export proceed through the nuclear pore complex (NPC). NPC is comprised of approximately 50 unique proteins collectively known as nucleoporins. NPC functions in the nuclear transport of protein and RNA. (NCI) | Nuclear pore complex|Nuclear pore apparatus|Nuclear Pore Complex|Complexus pori|NPC|Nuclear pore apparatus (cell structure)|nuclear pore complex (NPC)|nuclear pore complex|npc | Nuclear Pore Complex |
C1519628 | Any subcellular or molecular process involved in translocation of a biological entity, such as a macromolecule, from one site or compartment to another. | Transport Process|Transport Reaction|Transport|Molecular Transport | Molecular Transport |
C1278841 | null | Entire brachial plexus|Entire brachial plexus (body structure) | Entire brachial plexus |
C0751690 | A malignant neurilemmoma with nerve sheath differentiation. It is often associated with NEUROFIBROMATOSIS 1 and RHABDOMYOSARCOMA. | malignant peripheral nerve sheath tumor|MPNST - Malignant peripheral nerve sheath tumor|Malignant Neurilemmoma|SCHWANNOMA, MALIGNANT|Neurilemmosarcomas|Malignant Peripheral Nerve Sheath Tumors|Malignant Peripheral Nerve Sheath Neoplasm|Malignant Schwannoma, NOS|Malignant neurilemoma|Neurilemmoma, Malignant|Neurilemmosarcoma|Malignant Peripheral Nerve Sheath Tumor|Schwannoma, Malignant|Malignant schwannoma|Malignant Peripheral Nerve Sheath Tumour|Malignant peripheral nerve sheath tumor (disorder)|Malignant Tumor of Peripheral Nerve Sheath|Malig. periph. nerve sheath tum.|Malignant Neurilemomas|Malignant Schwannomas|Malignant Tumor of the Peripheral Nerve Sheath|Malignant neurilemmoma|Malignant peripheral nerve sheath tumor|MPNST|Neurofibrosarcoma|Neurogenic Sarcoma|Malignant Neoplasm of the Peripheral Nerve Sheath|Malignant Neurilemoma|Malignant Schwannoma|Malignant Neurilemmomas|Peripheral Nerve Sheath Tumors, Malignant|Malignant peripheral nerve sheath tumors|Malignant peripheral nerve sheath tumour|Malignant peripheral nerve sheath tumor (morphologic abnormality)|malignant schwannoma|Neurilemmoma, malignant|Neurofibrosarcoma, Malignant|Malignant Neoplasm of Peripheral Nerve Sheath|mpnst|MPNST - Malignant peripheral nerve sheath tumour|Schwannoma, malignant|Neurilemoma, Malignant | Malignant Peripheral Nerve Sheath Tumor |
C0027831 | An autosomal dominant inherited disorder (with a high frequency of spontaneous mutations) that features developmental changes in the nervous system, muscles, bones, and skin, most notably in tissue derived from the embryonic NEURAL CREST. Multiple hyperpigmented skin lesions and subcutaneous tumors are the hallmark of this disease. Peripheral and central nervous system neoplasms occur frequently, especially OPTIC NERVE GLIOMA and NEUROFIBROSARCOMA. NF1 is caused by mutations which inactivate the NF1 gene (GENES, NEUROFIBROMATOSIS 1) on chromosome 17q. The incidence of learning disabilities is also elevated in this condition. (From Adams et al., Principles of Neurology, 6th ed, pp1014-18) There is overlap of clinical features with NOONAN SYNDROME in a syndrome called neurofibromatosis-Noonan syndrome. Both the PTPN11 and NF1 gene products are involved in the SIGNAL TRANSDUCTION pathway of Ras (RAS PROTEINS). | Von Recklinghausen Disease|Clinical von Reclinghausen's disease|NEUROFIBROMATOSIS TYPE 1|Neurofibromatosis|von Recklinghausen's disease|Neurofibromatosis, Peripheral Type|NEUROFIBROMATOSIS, PERIPHERAL TYPE|Recklinghausen's Disease of Nerve|disease recklinghausens|Multiple non-ossifying fibromatosis|Neurofibromatosis, Type 1|Recklinghausen Disease of Nerve|Neurofibromatosis type 1|Molluscum Fibrosum|von recklinghausens disease|PHAKOMATOSIS RECKLINGHAUSEN|neurofibromatosis i|Recklinghausen's disease|Neurofibromatosis I|neurofibromatosis type i|Von Recklinghausen disease|NF1 (Neurofibromatosis 1)|Neurofibromatosis Type I|Neurofibromatosis, type 1|NF1|Type 1, Neurofibromatosis|Type I Neurofibromatoses|Neurofibromatosis Type 1|Type I, Neurofibromatosis|von Recklinghausen Disease|Neurofibromatosis, Type I|von Recklinghausens Disease|NEUROFIBROMATOSIS, TYPE I|Neurofibromatoses, Type I|NF1 - Neurofibromatosis type 1|Peripheral Neurofibromatoses|Neurofibromatosis, Peripheral|Neurofibromatosis, Peripheral, NF1|Peripheral Neurofibromatosis|Neurofibromatosis, peripheral type|Neurofibromatoses, Peripheral|von Recklinghausen's Disease|recklinghausen's disease|recklinghausen disease|Neurofibromatosis 1|Neurofibromatosis, type 1 [von recklinghausen's disease]|RECKLINGHAUSEN DISEASE|neurofibromatosis type 1|neurofibromatosis 1|von recklinghausen disease|Neurofibromatosis, Peripheral, NF 1|Type 1 Neurofibromatosis|VON RECKLINGHAUSEN DISEASE|von recklinghausen's disease|Neurofibromatosis Type 1 Microdeletion Syndrome|Neurofibromatosis type 1 (disorder)|Recklinghausen's neurofibromatosis|Recklinghausen Disease, Nerve|Recklinghausens Disease of Nerve|Von Recklinghausen's Disease | Neurofibromatosis 1 |
C0029468 | The surgical cutting of a bone. (Dorland, 28th ed) | Osteotomy, NOS|Division of bone, NOS|Osteotomy - action|surgical cutting of the bone|Division of bone|Osteotomy (procedure)|Osteotomy - action (qualifier value)|osteotomy|Osteotomy|Division of bone (procedure)|Transection of bone, NOS|osteotomies|Osteotomies | Osteotomy |
C1517885 | A procedure to avoid amputation of an arm or leg | Limb Sparing Procedure|Limb Salvage Procedures | Limb Salvage Procedure |
C0207072 | The founding member of the glial cell line-derived neurotrophic factor family. It was originally characterized as a NERVE GROWTH FACTOR promoting the survival of MIDBRAIN dopaminergic NEURONS, and it has been studied as a potential treatment for PARKINSON DISEASE. | Glial Cell-Line Derived Neurotrophic Factor|Glial Cell Line Derived Neurotrophic Factor|Glial Cell Line-Derived Neurotrophic Factor|GDNF|GDNF Growth Factor|gdnf|glial cell line derived neurotrophic factor (GDNF)|Growth Factor, GDNF | Glial Cell Line-Derived Neurotrophic Factor |
C0207072 | The founding member of the glial cell line-derived neurotrophic factor family. It was originally characterized as a NERVE GROWTH FACTOR promoting the survival of MIDBRAIN dopaminergic NEURONS, and it has been studied as a potential treatment for PARKINSON DISEASE. | Glial Cell-Line Derived Neurotrophic Factor|Glial Cell Line Derived Neurotrophic Factor|Glial Cell Line-Derived Neurotrophic Factor|GDNF|GDNF Growth Factor|gdnf|glial cell line derived neurotrophic factor (GDNF)|Growth Factor, GDNF | Glial Cell Line-Derived Neurotrophic Factor |
C0009402 | A malignant epithelial neoplasm that arises from the colon or rectum and invades through the muscularis mucosa into the submucosa. The vast majority are adenocarcinomas. | Colorectal cancer|Carcinomas, Colorectal|Large Bowel Carcinoma|Colorectal cancer, NOS|Carcinoma of Large Intestine|Cancer of Large Intestine|Large Intestine Cancer|Carcinoma of the Large Intestine|Carcinoma of the Large Bowel|Colorectal carcinomas|CRC|Colorectal Carcinomas|colorectal cancers|Large Bowel Cancer|Colorectal (Colon or Rectal) Cancer|Cancer of Large Bowel|Cancer of the Large Bowel|Colorectal carcinoma|Carcinoma, Colorectal|Colorectal Cancer|Colorectal Carcinoma|colorectal cancer|colorectal carcinoma|Colo-rectal cancer|Large Intestine Carcinoma|colon rectal cancer|Carcinoma of Large Bowel|carcinoma colorectal|COLORECTAL CANCER|colo-rectal cancer|Cancer of the Large Intestine | Colorectal Carcinoma |
C0054696 | null | carbohydrate deficient transferrin (CDT)|carbohydrate-deficient transferrin|C-D-transferrin|cdt|CDT|Carbohydrate deficient transferrin|Carbohydrate deficient transferrin (substance) | carbohydrate-deficient transferrin |
C0040679 | An iron-binding beta1-globulin that is synthesized in the LIVER and secreted into the blood. It plays a central role in the transport of IRON throughout the circulation. A variety of transferrin isoforms exist in humans, including some that are considered markers for specific disease states. | beta 1 Metal Binding Globulin|Siderophilin|Serotransferrin|Metal-Binding Globulin, beta-1|Transferrin (substance)|Iron binding protein|siderophilin|Globulin, beta-1 Metal-Binding|beta-1 Metal-Binding Globulin|Transferrin|transferrin | Transferrin |
C1261153 | null | drugs measurements|drug assay|drug level test|drug measurements|assays drug|drug level|drug measurement|drug levels|drugs levels | Drug measurement |
C0020980 | A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance. | immunoassays|Immunoassay|Immunoassay method|immunoassay|Immunoassays|Immunoassay method (procedure) | Immunoassay method |
C1516193 | The act of discovery of a malignant neoplasm, and after treatment, the discovery of minimal residual disease. | null | Cancer Detection |
C0678621 | null | null | separation method |
C0596799 | mass spectrometry in which the mass distribution of orbiting ions within a magnetic field is detected by bringing ion frequencies sequentially into resonance with applied radio frequencies. | null | ion cyclotron resonance spectrometry |
C0233763 | Optical perception of an object, person or event in the absence of a corresponding stimulus. | Visual hallucination|Visual hallucinations (finding)|visual hallucinations|Visual Hallucinations|seeing thing|Hallucination, visual|VISUAL HALLUCINATION|visual hallucination|Hallucination, Visual|seeing things|Visual hallucinations|Hallucinations Visual|Seeing things|HALLUCINATION VISUAL|Visual Hallucination|hallucinations visual|see things|see thing | Hallucinations, Visual |
C0010986 | The absence of light. | darkness|Darknesses | Darkness |
C0031765 | Treatment of disease by exposure to light, especially by variously concentrated light rays or specific wavelengths. | Actinotherapy|actinotherapy|Photoradiation Therapies|Phototherapy, NOS|photoradiation therapy|Therapy, Photoradiation|Therapy, Light|Photoradiation Therapy|Therapies, Light|light therapy|phototherapy|Therapies, Photoradiation|illumination therapy|Mental Health @ None @ Light Therapy @ None @ None @ None @ None|bright light therapy|phototherapies|Bright Light Therapy|Light therapy (procedure)|Phototherapies|Light Therapies|Phototherapy|Light therapy|Light Therapy | Phototherapy |
C0027789 | The two longitudinal ridges along the PRIMITIVE STREAK appearing near the end of GASTRULATION during development of nervous system (NEURULATION). The ridges are formed by folding of NEURAL PLATE. Between the ridges is a neural groove which deepens as the fold become elevated. When the folds meet at midline, the groove becomes a closed tube, the NEURAL TUBE. | Neural crest (body structure)|neural crest|Neural Crests|Crests, Neural|Crest, Neural|Neural Crest|crest neural|Neural crest | Neural Crest |
C0521422 | of relating to ear | Otic|otic | Otic |
C1514917 | A cis-acting transcription regulatory element. It is bound by the retinoic acid receptors. | RARE|Retinoic Acid Response Element | Retinoic Acid Response Element |
C0008046 | The developmental entity of a fertilized chicken egg (ZYGOTE). The developmental process begins about 24 h before the egg is laid at the BLASTODISC, a small whitish spot on the surface of the EGG YOLK. After 21 days of incubation, the embryo is fully developed before hatching. | chick embryo|Chick Embryos|Embryos, Chick|Embryo, Chick|chick embryos|Chick embryo | Chick Embryo |
C0949648 | The region of DNA which borders the 3' end of a transcription unit and where a variety of regulatory sequences are located. | Sequences, 3' Flanking|Flanking Region, 3'|Sequence, 3' Flanking|Flanking Sequence, 3'|3' Flanking Sequences|Flanking Sequences, 3'|Region, 3' Flanking|Regions, 3' Flanking|Flanking Regions, 3'|3' Flanking Sequence|3' Flanking Regions | 3' Flanking Region |
C0949645 | The region of DNA which borders the 5' end of a transcription unit and where a variety of regulatory sequences are located. | 5' Flanking Sequence|Region, 5' Flanking|Regions, 5' Flanking|Flanking Region, 5'|5' Flanking Sequences|Flanking Regions, 5'|Flanking Sequences, 5'|Sequence, 5' Flanking|Sequences, 5' Flanking|5' Flanking Regions|Flanking Sequence, 5' | 5' Flanking Region |
C0231024 | A tube of ectodermal tissue in an embryo that will give rise to the CENTRAL NERVOUS SYSTEM, including the SPINAL CORD and the BRAIN. Lumen within the neural tube is called neural canal which gives rise to the central canal of the spinal cord and the ventricles of the brain. For malformation of the neural tube, see NEURAL TUBE DEFECTS. | Neural tube structure (body structure)|Embryonic neuraxis|Tube, Neural|neural tubes|Neural Tube|Neural Tubes|Neural tube|Tubes, Neural|neural tube|medullary tube|Neural tube structure|tube neural | Neural tube |
C0682502 | null | Branchiostomatidae|amphioxi|Branchiostomidae|Family Branchiostomatidae|amphioxius|Family Branchiostomatidae (organism) | Branchiostomidae |
C0815004 | Neuroectodermal cells of the neural crest. They differentiate into various cell types during EMBRYOGENESIS including craniofacial MESENCHYME; ENDOCRINE CELLS; MELANOCYTES and PERIPHERAL NERVOUS SYSTEM. | Cell, Neural Crest|Neural crest cell|Neural crest cell group|Neural Crest Cell|embryonic neural crest cell|neural crest cell|cells crest neural|Set of neural crest cells|Neural crest cells|Aggregate of neural crest cells|Cells, Neural Crest | Neural Crest Cells |
C0001956 | null | Alcohol Use Disorders|alcohol use disorder|Use Disorders, Alcohol|alcohol use disorders|Use Disorder, Alcohol | Alcohol Use Disorder |
C0233477 | null | Dysphoria|DYSPHORIA|Dysphoric mood|Dysphoric mood (finding)|dysphoric mood|dysphoria | Dysphoric mood |
C0033968 | A generic term for the treatment of mental illness or emotional disturbances primarily by verbal or nonverbal communication. | Psychotherapy (regime/therapy)|talk therapy|psychotherapeutic technique|Psychotherapy, NOS|psychotherapies|Psychotherapies|psychotherapy|Psychotherapy | Psychotherapy |
C1527118 | The action of enzymes, regulators, chaperones etc. | protein function|Protein Function | Protein Function |
C0013936 | The process whose specific outcome is the progression of an embryo from its formation until the end of its embryonic life stage. The end of the embryonic stage is organism-specific. For example, for mammals, the process would begin with zygote formation and end with birth. For insects, the process would begin at zygote formation and end with larval hatching. For plant zygotic embryos, this would be from zygote formation to the end of seed dormancy. For plant vegetative embryos, this would be from the initial determination of the cell or group of cells to form an embryo until the point when the embryo becomes independent of the parent plant. [GOC:go_curators, GOC:isa_complete, GOC:mtg_sensu] | development embryological|embryological development|Embryonic Developments|Embryo Development|embryonal development|embryogenesis|embryo development|Embryonal Development|Embryonic Development|Embryogenesis|Development, Embryo|embryonic development|development embryonic|embryologic development|Development, Embryonic|Embryological development|Embryological development process|development embryo | Embryonic Development |
C1517331 | To or at a greater distance in time or space. | null | Further |
C0146712 | null | Diponium Bromide|Dipenine Bromide|2,2-Dicyclopentylacetic Acid 2'-diethylaminoethyl Ester Ethobromide|triethyl(2-hydroxyethyl)ammonium bromide dicyclopentyl acetate|DIPONIUM BROMIDE | diponium bromide |
C0146712 | null | Diponium Bromide|Dipenine Bromide|2,2-Dicyclopentylacetic Acid 2'-diethylaminoethyl Ester Ethobromide|triethyl(2-hydroxyethyl)ammonium bromide dicyclopentyl acetate|DIPONIUM BROMIDE | diponium bromide |
C0146712 | null | Diponium Bromide|Dipenine Bromide|2,2-Dicyclopentylacetic Acid 2'-diethylaminoethyl Ester Ethobromide|triethyl(2-hydroxyethyl)ammonium bromide dicyclopentyl acetate|DIPONIUM BROMIDE | diponium bromide |
C0006100 | A nonapeptide messenger that is enzymatically produced from KALLIDIN in the blood where it is a potent but short-lived agent of arteriolar dilation and increased capillary permeability. Bradykinin is also released from MAST CELLS during asthma attacks, from gut walls as a gastrointestinal vasodilator, from damaged tissues as a pain signal, and may be a neurotransmitter. | Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg|Callidin I|kallidin 9|Kallidin-9|bradykinin|Bradykinin|bradykinins|kallidin I|Arg-pro-pro-gly-phe-ser-pro-phe-arg|Kallidin I|BRS-640|BRADYKININ|Arg Pro Pro Gly Phe Ser Pro Phe Arg|L-bradykinin|Kallidin I (substance) | Bradykinin |
C0057109 | null | 1-Naphthalenesulfonic acid, 5-(dimethylamino)-hydrazide|dansylhydrazine | dansyl hydrazine |
C0009531 | null | null | Complement fixation test, adenovirus |
C0020275 | The first chemical element in the periodic table with atomic symbol H, and atomic number 1. Protium (atomic weight 1) is by far the most common hydrogen isotope. Hydrogen also exists as the stable isotope DEUTERIUM (atomic weight 2) and the radioactive isotope TRITIUM (atomic weight 3). Hydrogen forms into a diatomic molecule at room temperature and appears as a highly flammable colorless and odorless gas. | Hydrogen-1|HYDROGEN|Hydrogen (substance)|Hydrogen|H element|Protium|Hydrogen, NOS|H - Hydrogen|MOLECULAR HYDROGEN|hydrogen|hydrogen (H) | hydrogen |
C0558534 | The extraction of a sample of liver tissue taken via the insertion of a needle through the skin and into the liver. | Percutaneous liver biopsy (procedure)|Percutaneous Liver Biopsy | Percutaneous liver biopsy |
C1513388 | The use of molecular tools and techniques, especially gene and protein expression profiles, to diagnose disease. | molecular diagnosis|Molecular diagnosis | Molecular Diagnosis |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.